Iron-Deficiency Anemia Elevates Risk of Diabetic Kidney Disease in Type 2 Diabetes Mellitus

被引:0
作者
Huang, Bin [1 ]
Wen, Wenjie [2 ]
Ye, Shandong [1 ]
机构
[1] Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Endocrinol, Div Life Sci & Med, Hefei, Anhui, Peoples R China
[2] Wannan Med Coll, Wuhu, Anhui, Peoples R China
关键词
diabetic kidney disease; iron metabolism; iron supplementation; iron-deficiency anemia; Mendelian randomization; ASSOCIATION; DIAGNOSIS; CELLS;
D O I
10.1111/1753-0407.70060
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveThis study aims to explore the link between iron deficiency anemia (IDA) and diabetic kidney disease (DKD) and assess the safety of iron supplementation. It also investigates key mechanisms and molecules involved in iron deficiency's role in disease development.MethodsA retrospective analysis was conducted on 1,398 T2DM patients using propensity score matching to identify risk factors for DKD. Mendelian randomization (MR) was used to explore causal relationships between IDA, iron supplementation, liver iron content, and DKD. The GSE27999 dataset was analyzed to examine how an iron-deficient diet affects kidney-related gene expression. Key pathways and molecules were identified through GSEA, GO/KEGG, and PPI analysis.ResultsRetrospective data showed a correlation between hemoglobin levels and DKD risk. Logistic regression confirmed that IDA increased DKD risk independently of other factors. MR revealed a causal link between IDA and DKD, with no significant effect from iron supplementation. GSE27999 analysis identified 580 differentially expressed genes, enriched in pathways like cytokine signaling, oxidative biology, and small molecule transport. PPI analysis highlighted 10 key hub genes, including Cyp2d26 and Fgf4.ConclusionIDA increases susceptibility to DKD, possibly through oxidative stress and altered small molecule transport. However, iron supplementation does not appear to increase the risk of DKD.
引用
收藏
页数:11
相关论文
共 43 条
  • [1] Zeidan R.S., Han S.M., Leeuwenburgh C., Xiao R., Iron Homeostasis and Organismal Aging, Ageing Research Reviews, 72, (2021)
  • [2] De Franceschi L., Iolascon A., Taher A., Cappellini M.D., Clinical Management of Iron Deficiency Anemia in Adults: Systemic Review on Advances in Diagnosis and Treatment, European Journal of Internal Medicine, 42, pp. 16-23, (2017)
  • [3] Ganz T., New Regulators of Systemic Iron Homeostasis, Signal Transduction and Targeted Therapy, 6, 1, (2021)
  • [4] Long H., Zhu W., Wei L., Zhao J., Iron Homeostasis Imbalance and Ferroptosis in Brain Diseases, MedComm, 4, 4, (2020)
  • [5] Anderson E.R., Shah Y.M., Iron Homeostasis in the Liver, Comprehensive Physiology, 3, 1, pp. 315-330, (2013)
  • [6] Basak T., Kanwar R.K., Iron Imbalance in Cancer: Intersection of Deficiency and Overload, Cancer Medicine, 11, 20, pp. 3837-3853, (2022)
  • [7] Rayego-Mateos S., Rodrigues-Diez R.R., Fernandez-Fernandez B., Et al., Targeting Inflammation to Treat Diabetic Kidney Disease: The Road to 2030, Kidney International, 103, 2, pp. 282-296, (2023)
  • [8] Wang Y.H., Chang D.Y., Zhao M.H., Chen M., Dapagliflozin Alleviates Diabetic Kidney Disease via Hypoxia Inducible Factor 1alpha/Heme Oxygenase 1-Mediated Ferroptosis, Antioxidants & Redox Signaling, 40, 7-9, pp. 492-509, (2024)
  • [9] Lu Q., Yang L., Xiao J.J., Et al., Empagliflozin Attenuates the Renal Tubular Ferroptosis in Diabetic Kidney Disease Through AMPK/NRF2 Pathway, Free Radical Biology & Medicine, 195, pp. 89-102, (2023)
  • [10] Huang B., Wen W., Ye S., Dapagliflozin Ameliorates Renal Tubular Ferroptosis in Diabetes via SLC40A1 Stabilization, Oxidative Medicine and Cellular Longevity, 2022, (2022)